Floatz logo

Epclusa

Diabetes Mellitus

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)UNKNOWNPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

42 Active assets in the Diabetes Mellitus cohort.

Asset / SponsorPhaseRating
Metformin
Erbil Polytechnic University
Phase 4A
Pioglitazone
Milton S. Hershey Medical Center
Phase 4BBB
Alogliptin
Takeda
Phase 3BBB
Glibenclamide
Takeda
Phase 4BBB
Aspirin
Region Skane
Phase 4BBB

View all 49 →

Same molecule, other indications

Epclusa is also rated in:

chronic hepatitis C virus infectionActive
BB
Indicative · Phase 4
65 / 100
View asset →
opiate dependenceDormant
BB
Indicative · Phase 4
65 / 100
View asset →
metabolic bone disorderDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →